Skip to content

Search

Showing results for "Childhood interstitial lung disease "

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.

Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis

Palivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort

Medulloblastoma

Medulloblastoma is a highly malignant small round blue cell tumor of the posterior fossa

FBXO11, a regulator of the TGFΒ pathway, is associated with severe otitis media in Western Australian children

Otitis media (OM) is a common childhood disease characterised by middle ear inflammation following infection

Women Diagnosed with Ovarian Cancer: Patient and Carer Experiences and Perspectives

By directly engaging with women diagnosed with ovarian cancer, this study aimed to explore and identify their view of the health symptoms and outcomes that matter most to them as they traverse their disease pathway.

Poor diet seriously affects teens’ liver health

New research from Perth's The Kids for Child Health Research shows that a Western diet is associated with an increased risk of liver disease in teenag

BEACHES: Built Environments and Child Health in WalEs and AuStralia

The BEACHES project aims to provide high quality evidence of aspects of the built environment which can be modified to reduce the negative impact on children’s physical activity, eating behaviours and weight status.

FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies

Developmental and epileptic encephalopathies (DEE) are rare, often monogenic neurodevelopmental conditions. Most affected individuals have refractory seizures. All have multiple severe impairments which can be as life-limiting as or more limiting than the seizures themselves. Mechanism- and gene-targeted therapies for these individually rare, genetic conditions hold hope for treatment, amelioration of disease expression, and even cure. 

RHINO

RHINO researchers from The Kids' Wal-yan Respiratory Research Centre, will analyse ORIGINS data and turn it into meaningful respiratory and allergy outcome data that can be used by researchers around the world.